PDF herunterladen
CC BY 4.0 · World J Nucl Med 2023; 22(02): 130-134
DOI: 10.1055/s-0043-1760761
Case Report

Post-Topotecan Mixed Response and ‘Redifferentiation-akin’ Phenomenon on Dual Tracer PET-CT in Multiple Treatment-Resistant Metastatic Neuroendocrine Neoplasm

Sarvesh Loharkar
1   Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Parel, Mumbai, Maharashtra, India
2   Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Sandip Basu
1   Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Parel, Mumbai, Maharashtra, India
2   Homi Bhabha National Institute, Mumbai, Maharashtra, India
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

A 50-year-old female patient of heavily pre-treated (chemotherapy and multiple treatment-resistant) and progressive intermediate-grade metastatic neuroendocrine neoplasm is presented, wherein the lesions showed mixed response following topotecan treatment and multiple hepatic metastasis showed increase in the SSTR expression and decrease in FDG concentration on dual-tracer PET/CT (68Ga-DOTATATE and 18F-FDG PET/CT). Such observation allowed 177Lu-DOTATATE PRRT to be considered for an advanced, symptomatic, and multiple treatment-resistant patient with limited palliative treatment options left.

Keywords

neuroendocrine neoplasm - topotecan - 68Ga-DOTATATE - PET-CT - peptide receptor radionuclide therapy


Publikationsverlauf

Artikel online veröffentlicht:
28. April 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Popa O, Taban SM, Pantea S. et al. The new WHO classification of gastrointestinal neuroendocrine tumors and immunohistochemical expression of somatostatin receptor 2 and 5. Exp Ther Med 2021; 22 (04) 1179
    CrossrefPubMedSuche in Google Scholar
  • 2 Vélayoudom-Céphise FL, Duvillard P, Foucan L. et al. Are G3 ENETS neuroendocrine neoplasms heterogeneous?. Endocr Relat Cancer 2013; 20 (05) 649-657
    CrossrefPubMedSuche in Google Scholar
  • 3 Basu S, Ostwal V. Observation on enhanced avidity on somatostatin receptor targeted 68Ga-DOTATATE PET-CT following therapy with everolimus and capecitabine-temozolamide: is redifferentiation akin phenomenon a reality in neuroendocrine tumors?. Nucl Med Commun 2016; 37 (06) 669-671
    CrossrefPubMedSuche in Google Scholar
  • 4 Sharma P, Basu S. Occurrence of the redifferentiation-akin phenomenon on 68Ga-DOTATATE PET/CT after CAPTEM chemotherapy in metastatic neuroendocrine tumors with intermediate MIB1 index: what could be the molecular explanation?. J Nucl Med Technol 2020; 48 (03) 290-291
    CrossrefPubMedSuche in Google Scholar
  • 5 Apostolidis L, Bergmann F, Jäger D, Winkler EC. Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma. Cancer Med 2016; 5 (09) 2261-2267
    CrossrefPubMedSuche in Google Scholar
  • 6 Olsen IH, Knigge U, Federspiel B. et al. Topotecan monotherapy in heavily pretreated patients with progressive advanced stage neuroendocrine carcinomas. J Cancer 2014; 5 (08) 628-632
    CrossrefPubMedSuche in Google Scholar